Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - ibrutinib, quantity: 140 mg - capsule, hard - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; sodium lauryl sulfate; magnesium stearate; titanium dioxide; potable water; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - imbruvica is indicated for the treatment of patients with mcl who have received at least one prior therapy.,imbruvica as a single agent is indicated for the treatment of adult patients with waldenstr?m?s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.,imbruvica in combination with rituximab is indicated for the treatment of adult patients with waldenstrom?s macroglobulinaemia (wm).,imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia/small lymphocytic lymphoma (cll/sll).,imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (cll/sll) who have received at least one prior therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - temozolomide, quantity: 140 mg - capsule, hard - excipient ingredients: indigo carmine; colloidal anhydrous silica; tartaric acid; gelatin; lactose; sodium starch glycollate; stearic acid; titanium dioxide; purified water; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - temozolomide, quantity: 250 mg - capsule, hard - excipient ingredients: purified water; tartaric acid; stearic acid; lactose; sodium starch glycollate; gelatin; colloidal anhydrous silica; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - temozolomide, quantity: 180 mg - capsule, hard - excipient ingredients: tartaric acid; stearic acid; lactose; iron oxide yellow; purified water; sodium starch glycollate; gelatin; titanium dioxide; iron oxide red; colloidal anhydrous silica; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - temozolomide, quantity: 100 mg - capsule, hard - excipient ingredients: gelatin; titanium dioxide; purified water; colloidal anhydrous silica; tartaric acid; sodium starch glycollate; stearic acid; iron oxide red; lactose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - temozolomide, quantity: 20 mg - capsule, hard - excipient ingredients: lactose; iron oxide yellow; tartaric acid; stearic acid; titanium dioxide; gelatin; colloidal anhydrous silica; purified water; sodium starch glycollate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - temozolomide, quantity: 5 mg - capsule, hard - excipient ingredients: indigo carmine; colloidal anhydrous silica; iron oxide yellow; stearic acid; titanium dioxide; lactose; purified water; gelatin; sodium starch glycollate; tartaric acid; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ramipril, quantity: 10 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; brilliant blue fcf; allura red ac; gelatin; phloxine b - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. postmyocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure above 160 mmhg or diastolic blood pressure above 90 mmhg (or on antihypertensive treatment); total cholesterol above 5.2mmol/l: hdl cholesterol less than 0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim vetmedica gmbh - pimobendan - capsule, hard - 5 milligram(s) - pimobendan - dogs - cardiovascular

Australia - English - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - budesonide, quantity: 3 mg - capsule, modified release - excipient ingredients: sodium lauryl sulfate; iron oxide yellow; tributyl acetylcitrate; colloidal anhydrous silica; titanium dioxide; liquid paraffin; dimeticone 1000; purified talc; iron oxide black; ethylcellulose; gelatin; triethyl citrate; methacrylic acid copolymer; iron oxide red; polysorbate 80; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide; maize starch; sucrose - the induction of remission in adult patients with mild to moderate crohn's disease affecting the ileum and/or the ascending colon.